References
- Regulation (EC) No 141/2000 of the
European Parliament and of the Council of 16 December 1999 on orphan
medicinal products. Official Journal of the European Communities 2000;
L018(43):1–6.
- Council recommendation of 8 June 2009 on an action in the field of
rare diseases (2009/C 151/02). Official J Eur Union. 2009 Jul
3;52:7–10.
Availablefrom: http://eurlex.europa.eu/legalcontent/EN/TXT/?uri=OJ:C:2009:151:TOC ,
accessed 30 April 2021.
- https://rarediseases.info.nih.gov/diseases.
- Orphan Drug Act of 1983. US Food and Drug Administration. 4 January
1983.
- Richter T, Nestler-Parr S, Babela R; International Society for
Pharmacoeconomics and Outcomes Research Rare Disease Special Interest
Group. Rare Disease
Terminology and Definitions-A Systematic Global Review: Report of the
ISPOR Rare Disease Special Interest Group. Value Health 2015;
18:906-14. doi: 10.1016/j.jval.2015.05.008.
- https://rarediseases.org.
- Crea F. Emerging
causes and risk factors of heart failure: amyloidosis, myocarditis,
immune checkpoint inhibitors, air pollution, and visceral adipose
tissue. Eur Heart J. 2021; 42:1533-1537. doi:
10.1093/eurheartj/ehab214.
- Garcia-Pavia P, Rapezzi C, Adler et al
Diagnosis and
treatment of cardiac amyloidosis. A position statement of
the European Society of Cardiology Working Group on Myocardial and
Pericardial Diseases. Eur J Heart Fail. 2021 Apr 7. doi:
10.1002/ejhf.2140.
- van den Berg MP, Mulder BA, Klaassen SHC, Maass AH, van Veldhuisen DJ,
van der Meer P, Nienhuis HLA, Hazenberg BPC, Rienstra M. Heart failure
with preserved ejection fraction, atrial fibrillation, and the role of
senile amyloidosis. Eur Heart J 2019;40:1287–1293.
- Emdin M, Aimo A, Rapezzi C et al. Treatment of cardiac transthyretin
amyloidosis: an update. Eur Heart J 2019;40:3699–3706.
- Smith A, Balmforth D, Treibel T, Lall K, Oo A, Ambekar S. Cardiac
amyloidosis in non-transplant cardiac surgery. J Card Surg 2021 (In
press).
- Vaidya GN, Patel JK, Kittleson M et al.
Intermediate-term
outcomes of heart transplantation for cardiac amyloidosis in the
current era. Clin Transplant. 2021 Apr 7:e14308. doi:
10.1111/ctr.14308.
- Staron A, Connors LH, Zheng L, Doros G, Sanchorawala V.
Race/ethnicity in
systemic AL amyloidosis: perspectives on disease and outcome
disparities. Blood Cancer J. 2020; 10(11):118. doi:
10.1038/s41408-020-00385-0.
- Cheung RY, Cohen J, Illingworth P. Orphan Drug Plicies: Implications
fort he United States, Canada and developing countries. Health Law J
2004;12:183-200.